This international casee control study estimated radiation doses to the location of tumors within the stomach Purpose: To assess the doseeresponse relationship for stomach cancer after radiation therapy for cervical cancer. Methods and Materials: We conducted a nested, matched caseecontrol study of 201 cases and 378 controls among 53,547 5-year survivors of cervical cancer diagnosed from 1943 to 1995, from 5 international, population-based cancer registries. We estimated individual radiation doses to the site of the stomach cancer for all cases and to corresponding sites for the matched controls (overall mean stomach and showed for the first time a significant linear radiation doseeresponse relationship for risk of stomach cancer in long-term survivors of cervical cancer. tumor dose, 2.56 Gy, range 0.03-46.1 and after parallel opposed pelvic fields, 1.63 Gy, range 0.12-6.3). Results: More than 90% of women received radiation therapy, mostly with external beam therapy in combination with brachytherapy. Stomach cancer risk was nonsignificantly increased (odds ratio 1.27-2.28) for women receiving between 0.5 and 4.9 Gy to the stomach cancer site and significantly increased at doses !5 Gy (odds ratio 4.20, 95% confidence interval 1.41-13.4, P trend Z.047) compared with nonirradiated women. A highly significant radiation doseeresponse relationship was evident when analyses were restricted to the 131 cases (251 controls) whose stomach cancer was located in the middle and lower portions of the stomach (P trend Z.003), whereas there was no indication of increasing risk with increasing dose for 30 cases (57 controls) whose cancer was located in the upper stomach (P trend Z.23). Conclusions: Our findings show for the first time a significant linear doseeresponse relationship for risk of stomach cancer in long-term survivors of cervical cancer. Ó 2013 Elsevier Inc.
Introduction
Cervical cancer is the third most common cancer in women, with a worldwide burden of 530,000 cases and 275,000 deaths in 2008 (1) . In the United States there were 249,496 survivors of cervical cancer estimated to be alive in 2010 (2) . The majority of these survivors were treated with pelvic radiation therapy, and several previous studies have reported that cervical cancer survivors are at increased risk of developing a second cancer related to their radiation exposure (3) (4) (5) (6) (7) .
An estimated 17% (95% confidence interval [CI] 10%-23%) of second cancers after cervical cancer have been attributed to radiation therapy (8) , with the highest risks reported for second cancers of organs that are in or near the radiation field, such as the bladder and rectum. However, the data are sparse on cancer risks for gastrointestinal sites that are farther away from the radiation field and typically receive low to moderate radiation doses (<5 Gy). In particular, cohort studies of women treated for cervical cancer have reported 1.2-to 2-fold significantly increased risks of stomach cancer after radiation therapy compared with women not receiving radiation therapy (3) (4) (5) 7) , but these studies lacked detailed information on radiation dose. In a previous analytic study of women treated for cervical cancer that included individual radiation doses averaged across the entire stomach (mean dose, 2 Gy), Boice et al (6) reported a significant 2-fold risk of second stomach cancer compared with nonirradiated women, but there was no evidence that risk increased with increasing radiation dose. To clarify the association between radiation dose and stomach cancer risk among cervical cancer survivors, we conducted a caseecontrol study nested in a large population-based international cohort that included detailed radiation dose to the site of the stomach cancer for individuals.
Methods and Materials Study population
Five population-based cancer registries (Denmark, Finland, Iowa, Ontario, and Sweden) identified 53,547 5-year survivors of invasive cervical cancer. The registries reported 289 cases of second primary stomach cancer diagnosed at least 5 years after cervical cancer, with no previous invasive cancer other than a nonmelanoma skin cancer or in situ bladder cancer. Controls were individually matched 2:1 to cases by registry, race (Iowa only), birth date and cervical cancer diagnosis within 5 years, and survival without a subsequent primary cancer at least as long as the interval from date of cervical cancer diagnosis until date of stomach cancer diagnosis for the matched case. After exclusions due to unavailability of medical records (83 cases and 58 controls) and lack of matched controls (5 cases), the final study population consisted of 201 cases and 378 controls. Of these, 54 cases and 16 controls had been included in a previous caseecontrol study of stomach cancer after cervical cancer (6) .
Data collection
Abstractors collected data from medical records up to the date of the stomach cancer for cases and equivalent date for matched controls. Data included demographic variables, diagnosis and treatment of cervical cancer including radiation therapy and chemotherapy, recurrence of cervical cancer, subsequent treatment, and diagnosis of stomach cancer. Records were also reviewed for general cancer risk factors such as tobacco use, alcohol, height and weight, and family history of cancer, but data were too sparse to include in our analyses.
Stomach tumor location
Anatomic location of the stomach cancer was based on all available information, such as diagnostic pathology, radiology (barium studies, computed tomography scans) esophagoduodenoscopy, and surgical reports. We assumed a typical J-shaped stomach for a patient in the treatment (recumbent) position (9) . We classified the stomach tumor sites as proximal (upper stomach) or body and distal (middle and lower stomach). There were 40 cases with unknown tumor site (1 overlapping, not otherwise specified, and 39 unknown site).
Radiation treatment and dosimetry
Radiation therapy for cervical cancer consisted primarily of a combination of external beam and brachytherapy. External beam treatments typically were given in 1.5-to 3.0-Gy fractions over 4-6 weeks for a total dose of 30-50 Gy, depending on stage of disease. External beam energies included orthovoltage (160-400 kVp) (47.9%), 60 Co (19.1%), megavoltage photons (4-45 MV) (21.3%), combined energies (4.3%), and unknown energy (7.4%). The majority of women were treated with parallel-opposed anterior/ posterior pelvic fields (AP/PA pelvic fields) with typical heights between 10 and 18 cm. Less frequently used external beam fields included abdominal fields (above the umbilicus and below the diaphragm), perineal fields, and lateral and rotational pelvic fields. Brachytherapy was primarily low-dose-rate and delivered an average total of 6000 mghr (range, 1000-13,000 mghr). Five cases and 16 controls received high-dose-rate brachytherapy.
Radiation physics experts reviewed individual radiation treatment records and estimated radiation doses using a customdesigned dose program, based on water phantom measurements, which calculated doses to the stomach for each cervical cancer treatment field according to field location, size, laterality, and dose delivered (10) . The dose program takes into account 3 major external out of beam dose contributions, which include radiation leakage through the head of the machine, and scatter off the beam collimators and within the patient from the primary beam (see reference 10 for dosimetry details). Mean doses to the stomach tumor location were estimated for 182 cases and 337 controls. In addition, a radiation quality score was assigned to each patient, based on the completeness of radiation therapy data and ranging from 1 to 4 (1, complete; 2, not complete, omission not serious; 3, not complete, omission serious; and 4, inadequate for dosimetry). Individual radiation data were complete or nearly complete for 84.9% of cases and 83.4% of controls.
Statistical analysis
We used conditional logistic regression to estimate the relative odds (OR) of stomach cancer by comparing the exposure history of cases with their matched controls (11) . For radiation dosee response analyses, we compared dose to the site of the stomach cancer (and equivalent location for controls) to the referent category of nonirradiated women. For stomach tumors that involved more than one region (eg, antrum/pylorus), we assigned a dose on the basis of the mean dose to each specified site of involvement that was weighted according to the size of the stomach region. For those cases with overlapping (nZ1), multifocal (1), entire stomach (4), or unknown tumor location within the stomach (nZ39), mean dose to the entire stomach was assigned. Missing exposure data were handled by including an indicator variable (1, missing dose; 0, not missing) in the models. The OR for continuous radiation dose was expressed as 
Results
The median age at cervical cancer diagnosis was 54 years. Women were diagnosed over 5 decades from 1943 to 1995, with 65% of patients treated before 1970 ( Table 1 ). The majority of women had squamous cell cancer of the cervix. Second stomach cancer cases were diagnosed a mean of 17 years (range, 5-42 years) after cervical cancer. Histologic confirmation was available for 152 second stomach cancers (75.6%), with most cases classified as adenocarcinoma.
More than 90% of cases and controls were treated with radiation, and chemotherapy was rarely used. The mean dose to the stomach tumor site was 2.56 Gy (range, 0.3-46.1 Gy); the majority of cases (90.7%) and controls (95.3%) received <5 Gy. The most commonly used external beam field was AP/PA pelvis (113 cases and 216 controls) that delivered mean doses to the stomach tumor sites of 1.63 Gy (range, 0.12-6.3 Gy). The abdominal (mean, 26.5 Gy; 5 cases, 3 controls) and pelvic rotational fields (mean, 5.87 Gy; 5 cases, 11 controls) delivered the highest mean dose to the stomach tumor site (Fig. 1) .
Stomach cancer risk was nonsignificantly increased in irradiated women compared with nonirradiated women (OR 1.83, 95% CI 0.85-4.31) ( Table 2) . Although risks were nonsignificantly elevated between 0.5 and 4.9 Gy, risk significantly increased for women receiving !5 Gy to the stomach cancer site (OR 4.20, 95% CI 1.41-13.4). Modeling the risk associated with stomach doses >0-4.9 Gy and !5 Gy yielded ORs of 1.73 (95% CI 0.79-4.09) and 4.47 (95% CI 1.52-14.0), respectively. When dose was measured on a continuous scale, we observed a borderline significant linear increase in risk with increasing dose to stomach cancer site (P trend Z.047, EOR/Gy 0.11, 95% CI 0.001-0.48). Alternative analyses using a linear quadratic or linear exponential model did not improve the fit to these data (P trend >.50). Because of the wide dose range (5-46.1 Gy) in the highest dose category, we evaluated a more detailed model and noted consistently elevated risks above 5 Gy, with ORs of 3.6, 8.7, 3.5, and 4.7 for 5.0-6.9 Gy, 7.0-9.9 Gy, 10-14.9 Gy, and 15þ Gy, based on small numbers in each dose category. Overall, we estimated that stomach cancers in 37 of 1182 irradiated cervical cancer survivors (20%) in this study are attributed to radiation therapy.
The doseeresponse pattern for external beam therapy, adjusted for brachytherapy dose, was similar to analyses based on total dose, with significantly increased risks for doses !5 Gy (OR 3.61, 95% CI 1.18-12.1, P trend Z.052) ( Table 3) . We found no evidence that brachytherapy dose independently increased the risk of stomach cancer in analyses adjusted for external beam dose, with risks close to one in the highest dose group (!1.0 Gy, OR 1.03, 95% CI 0.36-3.02, P trend !.50).
In further analyses by type of external beam field, stomach cancer risk was low among women treated with the commonly used AP/PA pelvic radiation fields only (OR 1.22, 95% CI 0.65-2.35), adjusted for brachytherapy dose. Women receiving !5 Gy with only AP/PA fields had an OR of 2.93 (95% CI 0.68-12.7; 6 cases, 8 controls). However, risks were higher among women who received !5 Gy to the tumor site who were treated with other fields (eg, abdominal fields, rotational or lateral pelvic or perineal) (OR 5.91, 95% CI 1.68-23.0; 11 cases, 8 controls).
In analyses by stomach cancer site, we observed differences in risk for proximal stomach sites compared with body and distal sites. Among the 131 body or distal stomach cancers, we observed significantly increased risks after doses of 4-4.9 Gy (OR 4.48, 95% CI 1.06-20.3) and even greater increased risks for doses !5 Gy (OR 7.99, 95% CI 2.22-32.4, P trend Z.003) ( Table 4 ). The EOR/Gy for the body and distal stomach sites (0.281, 95% CI 0.04-1.08) was more than twice that for all stomach sites (EOR/Gy 0.11). Although numbers were small, there was no indication of increasing risk with increasing dose in separate analyses of 30 cases (and 57 matched controls) whose cancer was located in the proximal stomach (EOR/ Gy À0.024, 95% CI <À0.024, upper bound 0.067, P trend Z.23). None of the 30 proximal stomach cancer cases but 5 of 57 controls were exposed to doses !4 Gy. The linear doseeresponse for the body and distal stomach significantly differed from the proximal stomach (PZ.017), however, this difference seemed to be influenced by two controls who received high-dose radiation (30 Gy and 40 Gy) to the proximal stomach.
We also conducted a secondary doseeresponse analysis excluding stomach cancer cases (and matched controls) that occurred in more than one stomach region or had unknown specific stomach cancer site. The risk estimates for the remaining 148 cases/ 284 controls were OR 0.5 (95% CI 0.09-2.0; 4 cases/19 controls), 1.8 (95% CI 0.6-5.4; 20 cases/31 controls), 1.4 (95% CI 0.5-3.8; 42 cases/74 controls), 1.1 (95% CI 0.4-3.0; 31 cases/67 controls), 1.0 (95% CI 0.4-3.3; 17 cases/39 controls), 2.0 (95% CI 0.5-8.3; 8 cases/ 13 controls), and 2.7 (95% CI 0.8-9.8; 12 cases/13 controls) for radiation dose groups >0-0.49, 0.50-0.99, 1.0-1.9, 2.0-2.9, 3.0-3.9, 4.0-4.9, and !5 Gy, respectively, versus 0 Gy.
Stomach cancer risk (comparing 0.5-4.9 Gy and !5 Gy vs <0.5 Gy) seemed higher for women treated with radiation therapy for the 5-to 14.9-year time period after initial cancer diagnosis versus 15þ years (P homogeneity Z.10) ( Table 5 ). There was no evidence that radiation-related risks varied by calendar year of cervical cancer diagnosis or by age at diagnosis of either cervical cancer or stomach cancer. Results from sensitivity analyses restricted to women with complete or nearly complete radiation therapy records (163 cases, 292 controls) (EOR/Gy 0.099) and those with histologically confirmed stomach cancers (152 cases, 292 controls) (EOR/Gy 0.098) were similar to the full doseeresponse analyses based on 201 cases and 378 controls (EOR/Gy 0.11).
Discussion
This large international study of cervical cancer survivors showed for the first time that the risk of stomach cancer increased with increasing radiation dose from cervical cancer treatment. A unique feature of our international, population-based, caseecontrol study was estimation of the radiation dose to the anatomic location of the cancer within the stomach for individual cases (and equivalent location for matched controls), allowing more precise evaluation of the doseeresponse relationship. This study indicated that stomach cancer risk was nonsignificantly increased at doses from 0.5 to <5 Gy and then increased to a 4-fold significant risk at doses !5 Gy to the stomach tumor site. The availability of data on stomach tumor location further allowed us to evaluate risk separately for cancers in different stomach locations. We observed a highly significant linear doseeresponse relationship for risk of stomach cancers occurring in the body and distal sites that were closest to the radiation therapy fields and received the highest doses.
Although increased risks for radiation-related stomach cancer have been reported in several cohort investigations of women with cervical cancer (3) (4) (5) 7) , the relationship of radiation dose to risk has been evaluated in only one previous analytic casee control study (6) . Boice et al reported a significantly increased 2-fold risk of stomach cancer associated with radiation therapy, but risk did not clearly increase with increasing dose (P trend Z.20) (6) . In that study mean dose to the entire stomach was estimated for individuals, rather than dose to the specific location where the stomach cancer occurred. Because the mean dose to the stomach cancer location can vary as much as 5-fold across the stomach, using a mean dose for the entire organ could overestimate doses for the proximal stomach and underestimate doses for the body and distal stomach. The resulting dose misclassification would contribute to a flattening of the doseeresponse relationship. Our approach enabled us to identify a larger number of cases exposed to mean stomach tumor doses !3 Gy (47 cases) and !5 Gy (17 cases) compared with the Boice et al study, which reported only 35 cases !3 Gy. This allowed us to detect significantly increased risks at higher doses, particularly when we restricted the dosee response analysis to cases occurring in the body or distal stomach.
Our results add to the evidence of risk for radiation-related stomach cancer after high-dose radiation therapy from other medical studies (12) (13) (14) and from the atomic bomb survivors (15) . In particular, significant radiation doseeresponse relationships were noted for stomach cancer following both Hodgkin lymphoma and testicular cancer patients, for whom mean stomach doses were substantially higher compared with our study, mainly owing to abdominal field irradiation (mean dose 20.2 Gy for cases and mean 10.6 Gy for controls, P trend <.0001) (12) . In addition, incidence data from the atomic bomb survivors life span study indicated a significant linear dose response for stomach cancer for survivors exposed to lower doses, 4 Gy (P<.001), with no indication of nonlinearity (P>.5) after whole-body, acute exposures (15) . The Excess Relative Risk/Gy was 0.47 (90% CI 0.29-0.68) for females in the atomic bomb survivors life span study at attained age of 70 years with exposure at age 30 years. Analytic studies of patients irradiated for peptic ulcer (13) (mean stomach The size, shape, and location of the stomach are known to vary with body position, stomach contents, phase of respiration, abdominal muscle tone, and body type. A limitation of our study, as well as previous studies evaluating the association between radiation therapy and stomach cancer, was that the exact stomach position at the time of radiation therapy was unknown for individuals, and this position likely shifts over the course of radiation treatment. For cases in which the anatomic location of the stomach tumor was unknown, or covered multiple regions (eg, antrum/ pylorus), the mean dose was averaged over these regions. This uncertainty in the stomach position and exact location of tumor origin could result in misclassification of dose estimates, although it was likely to be similar for cases and controls. Although our overall results are consistent with a linear increase in risk with increasing radiation dose, misclassification of exposure at lower doses, at which the radiation-related risk is likely to be small, could account for the relatively flat doseeresponse we observed in this lower dose range (16) .
Results for patients treated with the commonly used AP/PA fields were reassuring in that stomach cancer risk was relatively low across the dose range, and only 6 cases received doses !5 Gy. Although numbers were small, the use of other fields (abdominal, pelvic rotational, and some perineal fields) that delivered high doses to the cancer site seemed to account for much of the increased risk in the !5-Gy dose group, but some of these fields (eg, pelvic rotational, perineal) are not frequently used currently. This is the first study to evaluate separately the dose-related risk associated with brachytherapy and external beam radiation. We found no evidence that the low doses delivered to the stomach from brachytherapy significantly increased the already elevated risks of stomach cancer associated with external beam therapy. However, only 54 survivors received brachytherapy alone. Nonetheless, a previous study of uterine corpus cancer patients reported a significantly increased 2-fold risk for second stomach cancer associated with brachytherapy when used without external beam therapy (mean stomach dose, 0.70 Gy; range, 0.2-1.8) (17) , suggesting that further study of stomach cancer risk associated with this radiation modality is needed. Table 2 . The median value was used to form subgroups by age and calendar year of diagnosis, latency, and year of stomach cancer diagnosis.
* Risk estimates compared both dose groups 0.50-4.99 and !5.00 Gy with referent group of survivors who were not exposed to radiation or received <0.50 Gy.
y Homogeneity in radiation-related risks among various subgroups was evaluated under a multiplicative model by comparing the fit of a model with separate ORs for each subgroup with a model with a single estimate for all survivors.
Conclusion
Our results demonstrated for the first time that radiation doses (!4-5 Gy) to the anatomic site of the tumor increase the risk of stomach cancer. Although dose uncertainties associated with dose and location of the stomach precluded precise quantification of risk in the lower dose range, our results are consistent overall with a linear doseeresponse relationship for stomach cancer, as would be predicted from the atomic bomb survivor study. It is important to recognize that increased risks of radiation-related stomach cancer should be balanced against the benefit of the radiation therapy. Radiation continues to be an essential and successful component of cervical cancer treatment. In high-risk patients requiring extended-field radiation therapy to achieve adequate tumor control, the reduction in risk of recurrence far outweighs the risk of second stomach cancer. Our findings emphasize the importance of evaluating the risk of second cancers in gastrointestinal organs outside the primary radiation field. Of particular interest is the current use of conformal methods and the emerging use of intensity modulated radiation therapy to treat more extensive cervical cancer (18) . Intensity modulated radiation therapy has been suggested to decrease the radiation dose to the normal tissue immediately surrounding the cancer site, yet possibly increase the dose to organs farther from the primary treatment field (19) . In addition, modern treatment protocols for cervical cancer recommend combination radiation therapy with platinum-based chemotherapy (chemoradiation) for cervical cancer patients with stage !IB disease (18) . Future studies will be needed to evaluate second cancer risk for organs at a distance from the cervix from these combined treatment approaches, quantify risk more precisely in the lower radiation dose range, and take into account doseevolume relationships and the dose to the stomach tumor location to the extent possible. Because the interval for radiation-related solid cancers is often 10 or more years after exposure, long-term follow-up studies will be needed for the large number of irradiated cervical cancer survivors treated in the past and to estimate risk among patients receiving current treatment approaches.
